Skip to main content
Premium Trial:

Request an Annual Quote

Nanogen Appoints Gerald Wills as CFO

NEW YORK, April 30 - Nanogen has appointed Gerald Wills, formerly the chief
financial officer of Trega Biosciences, as its vice president and chief financial officer, the San Diego-based company said Monday.

Wills, 48, will replace the current CFO Kieran Gallahue, who will now work solely as president of Nanogen.

Wills served in his position at Trega from 1999 until it was acquired by Lion Biosciences in March. Previously, Wills was chief financial officer of cardiac testing biotech company Molecular Biosystems.

Additionally, Nanogen reported that Randy White, the executive vice president of technical operations and R&D at American Medical Laboratories, has joined the company's board of directors.

Recently, White facilitated a collaboration between Nanogen and AML. Nanogen hopes the deal will lead to the development of molecular diagnostic assays for its NanoChip molecular biology workstation.

The Scan

UK Pilot Study Suggests Digital Pathway May Expand BRCA Testing in Breast Cancer

A randomized pilot study in the Journal of Medical Genetics points to similar outcomes for breast cancer patients receiving germline BRCA testing through fully digital or partially digital testing pathways.

Survey Sees Genetic Literacy on the Rise, Though Further Education Needed

Survey participants appear to have higher genetic familiarity, knowledge, and skills compared to 2013, though 'room for improvement' remains, an AJHG paper finds.

Study Reveals Molecular, Clinical Features in Colorectal Cancer Cases Involving Multiple Primary Tumors

Researchers compare mismatch repair, microsatellite instability, and tumor mutation burden patterns in synchronous multiple- or single primary colorectal cancers.

FarGen Phase One Sequences Exomes of Nearly 500 From Faroe Islands

The analysis in the European Journal of Human Genetics finds few rare variants and limited geographic structure among Faroese individuals.